uploads/2019/01/lab-217041_640.jpg

Analysts’ Recommendations for Merck & Co. in January

By

Updated

MRK’s price movements

On January 10, Merck & Co. (MRK) closed at $74.48, 1.23% lower than its previous closing price. The company closed at a premium of 40.98% to its 52-week low price of $52.83 and a discount of 7.12% to its 52-week high price of $80.19. On January 10, Merck & Co.’s market cap was $198.27 billion. The company was trading at a trailing PE ratio of 33.78x and a forward PE ratio of 15.82x.

Based on its closing price on January 10, the company had reported returns of 0.59% in the last week, -3.80% in the last month, and 2.96% in the last quarter. It had also reported returns of 20.32% in the last half year, 31.13% in the last year, and -2.53% YTD (year-to-date).

Article continues below advertisement

Based on its closing price on January 10, the broader market represented by the SPDR S&P 500 ETF (SPY) had reported returns of 6.01% in the last week, -1.97% in the last month, and -9.92% in the last quarter. SPY had also reported returns of -6.49% in the last half year, -5.70% in the last year, and 3.59% YTD.

While Merck & Co. has been underperforming the broader market ETF in the short term, the stock has mostly performed better than the market in 2018.

Analysts’ recommendations and target prices

The 12-month consensus analyst recommendation for Merck & Co. on January 11 was a “buy.” The 12-month consensus target price for the company was $81.32, 9.18% higher than its closing price on January 10. The highest target price estimate for the company was $96, and the lowest target price estimate was $63.

Of the 16 analysts covering Merck & Co. on January 10, six rated it as a “strong buy,” nine rated it as a “buy,” and only one rated it as a “hold.”

In the next article, we’ll discuss analysts’ recommendations for AbbVie (ABBV) in greater detail.

Advertisement

More From Market Realist